(OP:SDZNY)

82.62 +0.04 (+0.05%)

Delayed Quote Updated: 3:09 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about SDZNY

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor ↗

June 16, 2025

A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.

Via Benzinga

Topics Intellectual Property

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug ↗

April 14, 2025

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market.

Via Benzinga

Topics Intellectual Property Lawsuit

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗

February 24, 2025

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing...

Via Benzinga

Why Is Coherus BioSciences Stock Trading Higher On Tuesday? ↗

December 03, 2024

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Via Benzinga

Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

October 02, 2024

Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

Via News Direct

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars ↗

September 11, 2024

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.

Via Benzinga

3 Spinoff Stocks You Should Buy Now: July 2024 ↗

July 15, 2024

Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early.

Via InvestorPlace

Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗

July 04, 2024

Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.

Via InvestorPlace

Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab ↗

April 30, 2024

Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.

Via Benzinga

Topics Intellectual Property

February 29, 2024

Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchasers without admitting wrongdoing. Post-approval, litigation continues with...

Via Benzinga

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today? ↗

January 22, 2024

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.

Via Benzinga

Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases ↗

December 04, 2023

Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC:

Via Benzinga

Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More ↗

October 24, 2023

Novartis AG (NYSE: NVS) reported

Via Benzinga

Topics Earnings

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.